Five upcoming psychedelic clinical trials you don’t want to miss

1. A Multi-Site Study of MDMA-Assisted Psychotherapy for Eating Disorders (MED1)

Organised by MAPS, this Phase II study will explore the safety and feasibility of MDMA-assisted therapy (MDMA-AT) in the treatment of 18 participants with eating disorders.

2. An Open-Label, Phase 2, Feasibility Study of Manualized MDMA-Assisted Psychotherapy in Subjects with Major Depressive Disorder

The PsykForsk research team at Østfold hospital in Norway will conduct the world’s first trial using investigating MDMA-AT in people with major depressive disorder (MDD).

3. Evaluation of Psilocybin (TRP-8802) in the Treatment of Binge Eating Disorder

Tryp Therapeutics is planning a Phase IIa open-label study to determine the safety and feasibility of a single dose of their psilocybin formulation, TRP-8802, in people with binge eating disorder.

4. Study of the Safety and Feasibility of Psilocybin in Adults With Methamphetamine Use Disorder

Revive Therapeutics & the University of Wisconsin-Madison will investigate the safety and feasibility of two oral doses of psilocybin when combined with behavioural support for methamphetamine use disorder (MUD).

5. Effects of Psilocybin in Post-Treatment Lyme Disease

Researchers at Johns Hopkins University will examine the effects of psilocybin on Lyme disease symptom burden and quality of life in people with Post-Treatment Lyme Disease (PTLD).

--

--

Get the Medium app

A button that says 'Download on the App Store', and if clicked it will lead you to the iOS App store
A button that says 'Get it on, Google Play', and if clicked it will lead you to the Google Play store
Blossom

Blossom

Psychedelics information for everyone. Making info about psychedelics more accessible!